# Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn

> **Open Intelligence Dossier** · First detected: 2026-11-16 10:20 UTC · Category: Business

## Executive Summary
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.

## Intelligence Brief
Johnson &amp; Johnson announced it has agreed to buy the Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its pipeline of eye disease therapies, according to Endpoints News. The drugmaker stated it will acquire Ollin for $2.2 billion upfront, with the potential for regulatory and commercial milestone payments reaching up to about $1.13 billion. Some reports noted figures up to $3.4 billion, while Yahoo Finance and other outlets cited a Financial Times report mentioning up to $3.4bn.


Established in 2023, Ollin is backed by investment firms ARCH Venture Partners and Mubadala Capital to develop treatments for vision-threatening diseases. Through this acquisition, J&amp;J gains access to an experimental eye disease treatment, boosting its presence in a therapeutic area where it previously maintained a limited footprint despite its large contact lens business. Ollin is developing OLN324, an experimental drug intended to treat diabetic macular edema and wet age-related macular degeneration, which are two leading causes of vision loss.


According to Kip Connor, vice president, ophthalmology disease area stronghold leader at Johnson &amp; Johnson, OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control. Ollin reported that in a recent early-stage head-to-head study, the drug showed faster and greater improvements in eye structure and greater vision gains in both diabetic macular edema and wet age-related macular degeneration than Roche&#039;s Vabysmo. Ollin&#039;s pipeline also includes OLN102, which is currently in preclinical development for thyroid eye disease and Graves&#039; disease.


Ollin previously stated plans to begin late-stage studies testing OLN324 in the second half of this year, having raised $330 million in June to fund those trials. Additionally, Johnson &amp; Johnson said it will enter into a separate agreement with Blackstone Life Sciences. Blackstone will pay $750 million to the drugmaker over multiple years to fund the late-stage development of OLN324, and in turn, Blackstone will be eligible to receive payments and royalties. Endpoints News also noted that last week, Pfizer announced Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| BioSpace | J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxPeEhUMEFhQWlDRGNCYWZVT0htS2k5TFNLLVFPUVFwbjUtRXVZUC1aX3BPbjJWRTRRWWNrSmNCcGQxYUxKWlIweTdMZF9kckdmV2h0bTFDY0p6SHVKOHBOaUM2Mm91amlTRlpEaGlIREtsaFlxUEt4VXIzVlNfTmQ5Rmw5clpZaU1UXy12UjF4VG5MZHp0Q2wtQVBEVGM0VkdDbGRCc05YUQ?oc=5) |
| BioPharma Dive | J&J bets $2.2B on Ollin’s vision loss drug | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxOQkR5V3UzbExGT0QwOS10OU41NDdsZ0ZqODZzMjJnZmV3NlFtYnZBbFF2cjFyYVBCdXdvOXVBbmg1bWhrWVdzSG41c1dpTXQtMF81RnZ0N0NrdVBfdnF0MHFHWVlkOEFsNnEtSjV6cTBwMFpna1M5RFdDYmF5UEJGZ1dsRVJHLUx3QkVmOWpkcXVnTXBpWVhFbGRaNVIwSWpBUkFtSA?oc=5) |
| CNBC | J&J to buy eye disease biotech Ollin Biosciences for up to $3.3 billion | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNX3BHeG4tcm1XcjRpMXRnRC1CWmxTWklNYjdJZ0RQazBzRVA0MDFSUC1BUEZOc3U1dWFsT3g5WEh2TDhEYWlqNHprS094Rk1SRnRkRFZjakFWeGwwV0p4c0JiZUQzdGE2dnViQWx2UUFGNGpCOFpDNXAwbFJPZUdTQnpnVWxxeGk0ZTh5emh0TjdGV0paSjJ4cGhR0gGfAUFVX3lxTE1lLWV6bUpTbUFaZlpRakpJOGttN2RPckhRQzgwSjFGS3lERUJYNHkxcGNoSmJvaW1DeEJ0aUlvajhVdW5GU1dxc1A1T1JXeG5HbV9CQ3RwOWdFOUtQN1FyeGVMNmdULUFicVZKd2oyWlRrS1I2OHhZWHQyY0hRcks3Vi1ZOUxwMldEeFl2VjFWVTZJM0dzRjJYYjJqaTlUbw?oc=5) |
| WSJ | Johnson & Johnson to Buy Eye-Disease Biotech Ollin | [Source Link](https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT283S0x0NnNETXVQR0VYeGNpNE9QcVB5U0RCSVdCYVpISlo1MUY1bGEyRHotRGVvbHdoZUtCckh1RUViTGlKWDMzRlItQzlrMnZFUEtqbEphdmNvSTJiZlhtR29tMTdsU1BldmpIMmxzQTJFSEM4UEJ0Q2tBQzlQZEpCMmxYQldhRUppUW5Dc01GZlZmdk1Tb2ZfZ3puV29zc2NBQVNlSVh1LWI3akJHT0pWWUdBMzV4cTk5eFNZMzZDaUEyYUpwLW8wVmpSYzVaMWF5LTNmYTRWSTlVZkgzeGZ4bVhFbUFUY1VF?oc=5) |
| Endpoints News | J&J to buy eye disease biotech Ollin Biosciences for up to $3.3B | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxOenEtaU5lZjlrQ3hrUERKSEI3T3F3TVV6UVRFRFRsUkN0Wk5SdzJfS1phdmdLamR0ZzZ3UkFGS1BBZG9iVzczT2hFV0UxMS1HVXJEQVhPanBmVDhFbVhtUzcyUmNVN19TdF9oNnVJb0wwODRFQURSUHZNb3BaZGRJWEljMFZjZmR5V2J6eG9jdw?oc=5) |
| The Business Journals | Austin biotech startup to be acquired by Johnson & Johnson for $3.3B | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxOR0xLWlFxZE1aQUNLRnM2VmRJWWQ1NmVvUVhjQzhHQWZEMzlRLUMzTXp3R3NfOU9oV1ROaEhhZjF3WnpXWko1Yms2M2FsN1kyMjJySGIwRmdEbWFPYWlhR01GdzhxQk5rZnNST085V1ZFQ3dHWEtGa2lFMENFaWdXcktYMU5pSUdZcU83ZUh5Yzg5WkJ3eVloa1ZxTUxyQ19PT3JUZl9fNA?oc=5) |
| Fierce Biotech | J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxOMTZEd2FRR0ZDSlBkaUxwWkRicXVra3JsQ3BSWDdHdWoydlBfXzA3R05wOW1qdXpDMTlydklHR05BN1NqZl93UEdaZWdLaFZRXzUwYmhYa0VtVzJuV2x1NTkyTVBSV190U0d3RVUwSmRaY2pRdHkwaXl1NFZvbHFsYkNTUFZHR0VyazFISGplcmdwUQ?oc=5) |
| Business Wire | Blackstone Life Sciences Announces $750 Million R&D Funding Agreement | [Source Link](https://news.google.com/rss/articles/CBMixgFBVV95cUxOa3dQZUlaX2FCRFlWTVktdlFlblByOFktdEw0TFR1aWd1cUhvdV9FdWR6NlBFWkwzdGVKemR3NzN0bl8zeWtBOGZ4R2tOajJzRVpzM00tUWw4SVF1Z2dlblJ1aXhiRkNwMVdGWGV2WEtLM3g2WmZ5eGdybTBRLXFrajF0WGwxTC1lQU1lUkRmSkZkaGhXbGRYRm1FUG5mNFNNU2xqSzhJTndqbUdZc3ZlMC1oUDktQWVRM0F6M1dqM25CLWFFdmc?oc=5) |
| TradingView | J&J strikes $2.2 billion buyout deal for eye disease biotech | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxNd1NCalMyQUV3MnhKa2JWY0F5bmlIQ1hrR2EycnpKenBQR0txUVJGUFhyckduTGVCb1BMU0JYaXBMenlTZXQtelE4V2FWM0M4M1hjQ1pUYzRza2tjSFBRbUFuZGE2eVRteGhlVUtDaFRhUDJ3N2N6NjgxeUhMWlNTRHRZS0R2X2hmakc1OGNoeV93dUNWMXdfUkh5NXI4X3dTQzFhUl93cUlzN3ZBR3NLVkZfOFBCTEg0QUVKY0xWR3JBMl9ETlVaOQ?oc=5) |
| WSJ | Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion | [Source Link](https://news.google.com/rss/articles/CBMioAFBVV95cUxPU3VFMlB3aDIxS1Q1N0JpbEhDSWhHcmlXRklMdE52UzljRUF0OURHeFlpTmlnR3AxcHoyVFJ1MjJJbEdiS1FwN29WRXVXQjJTckdaQ1lvT3lfMGVZV3hLb3NlY1g3YkpPVnlXTUxDUjd5V3hTdFR3amFOZ3pPVXFoLVpNdmxFRUE3Q1RVN0NDVGRMVmZHMWJzVEY1Q1MyaXhU?oc=5) |
| marketscreener.com | Johnson & Johnson to Acquire Ollin Biosciences for Up to $3.33 Billion | [Source Link](https://news.google.com/rss/articles/CBMivAFBVV95cUxPMDNHZTRQbTVkY0txelFyOWNUcVQtd0l4elN4aU5uSnFGZG95OUlaZm0tb1dUM19qaHBTZDdiOERyZHA5SWtwT01qU25fX3VkSzhLWmFZQTVBT1EwYl9SeU0yX041ZHRRaTEzT0wxN1BhLVRnNzdaMTJlalJ1cDBSczNBU1BqdnNUMURhWDBqZ3pjTXVrQzMwMXZBYWk0Y1kxQUtYUFBINFVZMThtN0F4Mlk5YzFJUGJPQVE1eg?oc=5) |
| Reuters | J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences | [Source Link](https://news.google.com/rss/articles/CBMixgFBVV95cUxQOGMtOXhKbUJWVGR0ckFuVXhLTTJHODRRaExuTERnTlBCTFNTUFY1VUd2aXp5SUJrRHJCSkpIVFVZdVhaSzVWdk9xcW1rR05USV9rdjhTbkpGOHNvWWVkeUpackJYNUdaZnZjUUY2LVk3NTdFZDJybFg3RGdRbG9nd2hNZnEwZTZ5M2owakVjbUF4eXRUdEJlS3JNbWJZLUtpS0R6OEQ1OG1OZzlOc25hUVdjbWRrLU5nbndfWGswRGFUNE9NaXc?oc=5) |
| Business Wire | Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired | [Source Link](https://news.google.com/rss/articles/CBMigwJBVV95cUxPdXRNQW9KaTgxQ3VDUHNmVFc0VGdnc1Rob2pweXNCZVV0QVItcnozajc1STFCdmdORjUtN0JtWFFseVE0WVNUc1c0czlCa2IzUVpwSDRyMFctWXE5cmdvNWVYRHBZNlRuSTI2X1BFT0lJWWx5aVhQZ3BfQm9sNEstUDA4OUxVcVBzY3RBNkFNMXVMMkdCUmRLem4tN3c5M3JhMUgxeWlHc25mLW8wZlJjWjh4RUNHZ2JZVnhib084cE9EQ2N1UXNHVS1pY2NqcGZsLXVCYUg5WUtoTGJQUkdkTFhQMm9fV0R0Ui1BSzBWS1NHd0hvakxrVXBWTk8tMVhPdkQw?oc=5) |
| Business Wire | Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology | [Source Link](https://news.google.com/rss/articles/CBMijwJBVV95cUxPVVdjRHA1eXZqVk5wd3dVVnRYR3VTQ3laekZheENoZjVxOVdtY2RnVk5ON0lLYjdza3YzcHh0ZzdQalI4MFhqNE1vNEppemc3UG1Rb2FFLS1nMEtoYzFrSFB1MnZtaHRyRmEzenNaZHlsQVN2ZC0xMlRpRzY2cVE2cmtUNWRXWWtVM1dpUFo3Z2RlaTczYXNLTnZJcTJ5NG1ENXhyVWUydjhmX2lHS3RfVjljUzZ6Z05Ic2dPQ2ZzbjJOSXJ0WDZtZi03VWxITTQ3ZDBQSElENGRpRVBHZkdQYkxhajVpbDBETHdfWVFwbnkzLXFVMVFGZWRZRFFhRXRrNENfN0tnNnd2Yl9rc2VB?oc=5) |
| Yahoo Finance | J&J looks to buy Ollin Biosciences for up to $3.4 billion, FT says | [Source Link](https://news.google.com/rss/articles/CBMihwFBVV95cUxNVDdoMUVmUElPQWl5cUQ5T05hRnlDZW5iR2xqRVlfOUowRnpJemQ3bmM5N2FHMEhabENZR0FQSWJWbzhteHlrVi0xdWY3dS1yZWNJMjA2WEZ3QlVabHRERXV3RVdSa0lwWlhrZkk2X1JMNkpTdHlXTXhNTk1ZbmdYUTdhYkdjUnc?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-16/johnson-johnson-looking-to-buy-eye-disease-biotech-for-up-to-3-4bn*
